FDA grants RPDD to ReviR’s RTX-117 for CMT

By Salong Debbarma

ReviR Therapeutics has received a rare paediatric disease designation (RPDD) from the US Food and Drug Administration (FDA) for RTX-117, its investigational oral small-molecule therapy for Charcot-Marie-Tooth disease (CMT).